Moreover, because the elevated PARP1 expression in response to oxidative/nitrosation stress has been found in many different neurological diseases, repurposing or developing novel PARP1 inhibitors as neurotherapeutic agents have piqued the interest of researchers (6). The gene discussed is PARP1; the disease is nervous system disorder.